Our Portfolio Planning & Risk Management Tutorials Part 1 & 2 are now available at HS Talks <read more here>                     We invite you to meet us at the BIO Europe Convention in Berlin, November 6-8 <contact info>                     Our Portfolio Planning & Risk Management Tutorials Part 1 & 2 are now available at HS Talks <read more here>                     We invite you to meet us at the BIO Europe Convention in Berlin, November 6-8 <contact info>                     Our Portfolio Planning & Risk Management Tutorials Part 1 & 2 are now available at HS Talks <read more here>                     We invite you to meet us at the BIO Europe Convention in Berlin, November 6-8 <contact info>                     Our Portfolio Planning & Risk Management Tutorials Part 1 & 2 are now available at HS Talks <read more here>                     We invite you to meet us at the BIO Europe Convention in Berlin, November 6-8 <contact info>                    
 
Home      About      Team      Clients      Publications      Downloads      News      Contact            

Testimonials
  Both, breadth and depth of Bioscience Valuation's economic assessments as well as the company's excellent knowledge of healthcare markets are invaluable assets for me in order to reach my goals.

Rick Jackson, Chairman and CEO
Jackson Healthcare

 

Core Services
  Financial Valuation
  Commercial Assessment &
Pharmacoeconomics

  R&D Risk Analysis &
Productivity Increase

  Portfolio Management
  Investment Decisions
  Partnering / Licensing
  Corporate Finance / M&A

Special Expertise
  Economic Modeling
of Healthcare Systems

  Assessing the Economics
of Personalized Medicine

Comprehensive Support
  Corporate Partnership Program

Products
  Market Model
  R&D Risk Model
  Valuation Model

Core Services - Partnering / Licensing

Bioscience Valuation supports senior management in Partnering (e.g., in- and outlicensing) efforts:
  • full evaluation of the asset, including all commercial, R&D and financial attributes,
  • creation of long and short lists of potential partners,
  • initiating contact and communication between client and target company,
  • drafting term sheets,
  • supporting the negotiations until an agreement has been signed,
  • monitoring partnership progress and ensuring satisfaction of all parties after the deal.


Case:
A leading Southern-European company was searching for in-licensing opportunities. Bioscience Valuation (BSV) screened the worldwide pharmaceutical markets in a comprehensive and systematic way.

Bioscience Valuation identified promising drugs that were EMA-approved and ready to get marketed; BSV drafted the term sheet and supported the negotiations. Bioscience Valuation's client licensed the drug that is now distributed in the local market.